Pharmacokinetics of meropenem in critically Ill patients with severe infections

Therapeutic Drug Monitoring

Volumn 35, Issue 1, 2013, Pages 63-70

  Binder, Lutz ^a   Schwörer, Harald ^a   Hoppe, Sebastian ^a   Streit, Frank ^a   Neumann, Silke ^a   Beckmann, Annett ^a   Wachter, Rolf ^a   Oellerich, Michael ^a   Walson, Philip D ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

critically ill patients; inadequate dosing; meropenem; pharmacokinetics; therapeutic drug monitoring

Indexed keywords

MEROPENEM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; FEMALE; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; HUMANS; INFECTION; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; THIENAMYCINS;

EID: 84872834781     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31827d496c     Document Type: Article

References (46)

1. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34:17-61.
2. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-1596.
3. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antimicrobial therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31:2742-2751.
4. Ariano RE, Nyhlen A, Donnelly JP, et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2005;39:32-38.
5. Schuster H-P, Werdan K. Intensivtherapie bei Sepsis und Multiorganversagen. 3. Auflage. Berlin, Germany: Springer Verlag; 2000.
6. Behre G, Link H, Maschmeyer G, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol. 1998;76:73-80.
7. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother. 1995;35:139-148.
8. Kelly HC, Hutchison M, Haworth SJ. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min. J Antimicrob Chemother. 1995;36(suppl A):35-41.
9. Drusano GL, Lode H, Edwards Jr. Meropenem: clinical response in relation to in vitro susceptibility. Clin Microbiol Infect. 2000;6:185-194.
10. Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989;24:311-320.
11. Chimata M, Nagase M, Suzuki Y, et al. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with endstage renal disease. Antimicrob Agents Chemother. 1993;37:229-233.
12. Christensson BA, Nilsson-Ehle I, Hutchison M, et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992;36:1532-1537.
13. Dreetz M, Hamacher J, Eller J, et al. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother. 1996;40:105-109.
14. Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs. 2000;59:653-680.
15. Leroy A, Fillastre JP, Borsa-Lebas F, et al. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother. 1992;36:2794-2798.
16. Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet. 1995;28:275-286.
17. Sieger B. Meropenem monotherapy as empiric treatment of nosocomial lower respiratory tract infection. Crit Care Med. 1998;26:1462-1463.
18. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin. 2011;27:19-34.
19. Novelli A, Adembri C, Livi P, et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet. 2005;44:539-549.
20. Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents. 2002;19:105-110.
21. Roberts JA, Kirkpatrick CM, Roberts MS, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142-150.
22. Jaruratanasinkul S, Limapichat T, Juliangkoon M, et al. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteremia. Int J Antimicrob Agents. 2011;38:231-236.
23. Kim A, Kuti JL, Girotto JE, et al. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther. 2009;31:2765-2778.
24. Stockhausen K. The Declaration of Helsinki: revising ethical research guidelines for the 21st century. Med J Aust. 2000;172:252-253.
25. Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis. 1997;28:157-163.
26. Turner PJ. Mystic (Meropenem Yearly susceptibility test information collection): a global overview. J Antimicrob Chemother 2000;46:Suppl T2, 9-23.
27. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
28. Feld R, DePouw B, Berman S, et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol. 2000;18:3690-3698.
29. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J Antimicrob Chemother. 1996;38:523-537.
30. Cars O. Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics. Diagn Microbiol Infect Dis. 1997;27:29-33.
31. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10.
32. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27:10-22.
33. Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokineticpharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis. 2006;42:1764-1771.
34. Lamoth F, Buclin T, Csajka C, et al. Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. Antimicrob Agents Chemother. 2009;53:785-787.
35. Thalhammer F, Traunmüller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother. 1999;43:523-527.
36. Nyhlen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group. Eur J Clin Microbiol Infect Dis. 1997;16:797-802.
37. Daenen S, Erjavec Z, Uges DR, et al. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis. 1995;14:188-192.
38. Pea F, Viale P, Damiani D, et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother. 2005;49:3550-3553.
39. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009-1034.
40. Bedikian A, Okamoto MP, Nakahiro RK, et al. Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother. 1994;38:151-154.
41. de Stoppelaar F, Stolk L, van Tiel F, et al. Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J Antimicrob Chemother. 2000;46:150-151.
42. Giles LJ, Jennings AC, Thomson AH, et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med. 2000;28:632-637.
43. Tegeder I, Neumann F, Bremer F, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther. 1999;65:50-57.
44. Karjagin J, Lefeuvre S, Oselin K, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther. 2008;83: 452-459.
45. van Lent-Evers NA,Mathôt RA, GeusWP, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999;21:63-73.
46. Li C, Kuti JL, Nightingale CH, et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol. 2006;46:1171-1178.